Competition is close for top positions
Pharmaceutical companies continue to inch forward in addressing access to medicine in low- and middle-income countries, finds the 2021 Access to Medicine Index. Pfizer moves into the top five. GSK retains its number one position, yet only slightly ahead of Novartis.
1 | GlaxoSmithKline plc |
0
1
2
3
4
5
|
4.59 | |
GlaxoSmithKline plcRead more |
||||
1 | Takeda Pharmaceutical Co. Ltd. |
0
1
2
3
4
5
|
4.59 | |
Takeda Pharmaceutical Co. Ltd.Read more |
||||
2 | Novartis AG |
0
1
2
3
4
5
|
4.39 | |
Novartis AGRead more |
||||
3 | AstraZeneca plc |
0
1
2
3
4
5
|
4.32 | |
AstraZeneca plcRead more |
||||
4 | Johnson & Johnson |
0
1
2
3
4
5
|
4.25 | |
Johnson & JohnsonRead more |
||||
5 | Novo Nordisk A/S |
0
1
2
3
4
5
|
4.12 | |
Novo Nordisk A/SRead more |
||||
5 | Pfizer Inc. |
0
1
2
3
4
5
|
4.12 | |
Pfizer Inc.Read more |
||||
6 | Roche Holding AG |
0
1
2
3
4
5
|
4.08 | |
Roche Holding AGRead more |
||||
7 | Merck KGaA (Merck) |
0
1
2
3
4
5
|
3.75 | |
Merck KGaA (Merck)Read more |
||||
8 | Bayer AG |
0
1
2
3
4
5
|
3.55 | |
Bayer AGRead more |
||||
8 | Eisai Co. Ltd. |
0
1
2
3
4
5
|
3.55 | |
Eisai Co. Ltd.Read more |
||||
9 | Astellas Pharma Inc. |
0
1
2
3
4
5
|
3.46 | |
Astellas Pharma Inc.Read more |
||||
10 | Boehringer Ingelheim GmbH |
0
1
2
3
4
5
|
3.28 | |
Boehringer Ingelheim GmbHRead more |
||||
11 | Sanofi |
0
1
2
3
4
5
|
3.05 | |
SanofiRead more |
||||
12 | Gilead Sciences Inc. |
0
1
2
3
4
5
|
2.89 | |
Gilead Sciences Inc.Read more |
||||
13 | Eli Lilly & Co. |
0
1
2
3
4
5
|
2.85 | |
Eli Lilly & Co.Read more |
||||
14 | Merck & Co., Inc. (MSD) |
0
1
2
3
4
5
|
2.80 | |
Merck & Co., Inc. (MSD)Read more |
||||
15 | Bristol Myers Squibb Co. |
0
1
2
3
4
5
|
2.70 | |
Bristol Myers Squibb Co.Read more |
||||
16 | Daiichi Sankyo Co. Ltd. |
0
1
2
3
4
5
|
2.54 | |
Daiichi Sankyo Co. Ltd.Read more |
||||
17 | AbbVie Inc. |
0
1
2
3
4
5
|
2.52 | |
AbbVie Inc.Read more |
0
1
2
3
4
5
|
The ranking above shows the position and score of each company in the 2021 Index. Click on a company's name to go to its full report card.
Insights
-
11 companies view access as a business matter
More than half companies demonstrate good practice by embedding their access-to-medicine strategy within their overall business strategy and across all therapeutic areas they are involved in. This indicates that access thinking is incorporated consistently within the company.
-
12 companies ensure top level accountability
More than half of the companies provide managers and senior executives with incentives to achieve access-to-medicine goals. Top-level accountability is likely to filter into the rest of the company and can help enable teams within the company to deliver on access-to-medicine initiatives.
-
Incentives move away from sales targets
Over half of the companies have incentives that are not wholly linked to sales. By moving away from rewards pegged primarily against sales targets, companies can limit the the risk of misselling (i.e. the act of selling a product to a person when it is not necessary or not adapted for them) or over-selling products.
-
8 companies stand out for their compliance controls
Eight companies demonstrate best practice by applying all the compliance controls looked for by the Index, i.e., processes for checking and detecting non-compliance that might negatively affect access to medicine, supported by rigorous monitoring and auditing.